PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW000519View Pathway |
disease
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)Homo sapiens
Methylenetetrahydrofolate reductase deficiency (MTHFRD; Homocystinuria due to defect of n(5,10)-methylene THF deficiency) is caused by a defect in the MTHFR gene which codes for methylenetetrahydrofolate reductase. Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. A defect in this enzyme results in accumulation of homocysteine and methionine in both plasma and urine. Some of the symptoms and signs include mental retardation, withdrawal, hallucinations, delusions, muscle weakness. Some patients remain asymptomatic until adulthood.
|
Creator: WishartLab Created On: August 29, 2013 at 10:39 Last Updated: August 29, 2013 at 10:39 |
PW127247View Pathway |
disease
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)Homo sapiens
Methylenetetrahydrofolate reductase deficiency (MTHFRD; Homocystinuria due to defect of n(5,10)-methylene THF deficiency) is caused by a defect in the MTHFR gene which codes for methylenetetrahydrofolate reductase. Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. A defect in this enzyme results in accumulation of homocysteine and methionine in both plasma and urine. Some of the symptoms and signs include mental retardation, withdrawal, hallucinations, delusions, muscle weakness. Some patients remain asymptomatic until adulthood.
|
Creator: Ray Kruger Created On: November 22, 2022 at 11:06 Last Updated: November 22, 2022 at 11:06 |
PW000104View Pathway |
disease
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)Homo sapiens
Methylenetetrahydrofolate reductase deficiency (MTHFRD; Homocystinuria due to defect of n(5,10)-methylene THF deficiency) is caused by a defect in the MTHFR gene which codes for methylenetetrahydrofolate reductase. Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. A defect in this enzyme results in accumulation of homocysteine and methionine in both plasma and urine. Some of the symptoms and signs include mental retardation, withdrawal, hallucinations, delusions, muscle weakness. Some patients remain asymptomatic until adulthood.
|
Creator: WishartLab Created On: August 01, 2013 at 15:52 Last Updated: August 01, 2013 at 15:52 |
PW128112View Pathway |
drug action
Methylergometrine Mechanism of Action Action PathwayHomo sapiens
Methylergometrine is a semisynthetic ergot alkaloid and a derivative of ergonovine. It is also known as methylergonovine. Methylergometrine acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions through binding and the resultant antagonism of the dopamine D1 receptor. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. It is used for the prevention and control of postpartum and post-abortion hemorrhage. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result.
|
Creator: Omolola Created On: July 19, 2023 at 09:24 Last Updated: July 19, 2023 at 09:24 |
PW176340View Pathway |
Methylergometrine Predicted Metabolism PathwayHomo sapiens
Metabolites of sildenafil are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 15:17 Last Updated: December 07, 2023 at 15:17 |
PW146985View Pathway |
Methylergonovine Drug Metabolism PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 10, 2023 at 13:35 Last Updated: October 10, 2023 at 13:35 |
PW341680View Pathway |
Methylglyoxal Degradation IVeillonella dispar ATCC 17748
The degradation of methylglyoxal starts with methylglyoxal being degraded by interacting with glutathione and a glyoxalase resulting in the release of a (R)-S-lactoylglutatione. This compound in turn reacts with a water molecule through a glyoxalase II resulting in the releas of glutathione, a hydrogen ion and an R-lactate. The R-lactate in turn reacts with an ubiquinone through a D-lactate dehydrogenase resulting in the release of an ubiquinol and a pyruvate which can then be incorporated the pyruvate metabolism
|
Creator: Julia Wakoli Created On: October 31, 2024 at 09:40 Last Updated: October 31, 2024 at 09:40 |
PW355819View Pathway |
Methylglyoxal Degradation IEscherichia coli O157:H7 str. EC4115
The degradation of methylglyoxal starts with methylglyoxal being degraded by interacting with glutathione and a glyoxalase resulting in the release of a (R)-S-lactoylglutatione. This compound in turn reacts with a water molecule through a glyoxalase II resulting in the releas of glutathione, a hydrogen ion and an R-lactate. The R-lactate in turn reacts with an ubiquinone through a D-lactate dehydrogenase resulting in the release of an ubiquinol and a pyruvate which can then be incorporated the pyruvate metabolism
|
Creator: Julia Wakoli Created On: November 11, 2024 at 20:27 Last Updated: November 11, 2024 at 20:27 |
PW355833View Pathway |
Methylglyoxal Degradation IEscherichia coli O55:H7 str. CB9615
The degradation of methylglyoxal starts with methylglyoxal being degraded by interacting with glutathione and a glyoxalase resulting in the release of a (R)-S-lactoylglutatione. This compound in turn reacts with a water molecule through a glyoxalase II resulting in the releas of glutathione, a hydrogen ion and an R-lactate. The R-lactate in turn reacts with an ubiquinone through a D-lactate dehydrogenase resulting in the release of an ubiquinol and a pyruvate which can then be incorporated the pyruvate metabolism
|
Creator: Julia Wakoli Created On: November 11, 2024 at 20:32 Last Updated: November 11, 2024 at 20:32 |
PW355814View Pathway |
Methylglyoxal Degradation IEscherichia coli APEC O1
The degradation of methylglyoxal starts with methylglyoxal being degraded by interacting with glutathione and a glyoxalase resulting in the release of a (R)-S-lactoylglutatione. This compound in turn reacts with a water molecule through a glyoxalase II resulting in the releas of glutathione, a hydrogen ion and an R-lactate. The R-lactate in turn reacts with an ubiquinone through a D-lactate dehydrogenase resulting in the release of an ubiquinol and a pyruvate which can then be incorporated the pyruvate metabolism
|
Creator: Julia Wakoli Created On: November 11, 2024 at 20:25 Last Updated: November 11, 2024 at 20:25 |